We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1,a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Our corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland.
